Abstract：Objective To investigate the application value of percutaneous coronary intervention (PCI) in the treatment of ischemic cardiomyopathy. Methods Ninety-six patients with ischemic cardiomyopathy admitted to Zhongxiang People′s Hospital from February 2014 to April 2015 were selected and randomly divided into two groups by random coin tossing method, with 48 cases in each group. The control group received conventional drug therapy, on basis of which, the observation group was given PCI. After treatment, the biochemical indexes, cardiac function and adverse events during follow-up in the two groups were compared. Results After treatment for 1 month, the levels of brain natriuretic peptide (BNP), troponin I (TnI) and creatine kinase isoenzyme (CK-MB) in the two groups were all significantly improved compared with those before treatment, the levels of BNP, TnI, CK-MB in the observation group were significantly lower than those of control group, the differences were statistically significant (P ＜ 0.05). After treatment for 1 month, the levels of left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD) in the two groups were all significantly improved compared with those before treatment, the levels of LVEF in the observation group were significantly higher than those of control group, the levels of LVEDD in the observation group were significantly lower than those of control group, the differences were statistically significant (P ＜ 0.05). During follow-up, there was no statistically significant difference of the incidence of acute myocardial infarction between the two groups (P ＞ 0.05); compared with control group, the incidence of heart failure, angina and readmission in the observation group was significantly decreased, the differences were statistically significant (P ＜ 0.05). Conclusion PCI in the treatment of ischemic cardiomyopathy has high application value, which can effectively improve the cardiac function and the levels of BNP, TnI and CK-MB, reduce the incidence of adverse events. It is worthy of clinical promotion.
2017, Vol. 14 
京公网安备 11010502046598号